1 unchanged sentence
Rule 10b5-1 Trading Arrangements
−Removed: During the three months ended March 31, 2026 , no ne of our directors or officers, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: During the three months ended June 30, 2026, none of our directors or officers, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as set forth below:
+Added: • Lance Kurata , our Chief Legal Officer , adopted a Rule 10b5-1 trading arrangement as of May 15, 2026 .
+Added: Kurata's trading arrangement provides for the exercise of options to purchase up to 30,000 shares of common stock and the subsequent sale of up to an aggregate of 30,000 shares of common stock, beginning on August 14, 2026 and ending on March 31, 2027 .
+Added: Padmanabh Chivukula , Chief Scientific Officer and Chief Operating Officer , adopted a Rule 10b5-1 trading arrangement on May 14, 2026 .
+Added: Chivukula’s trading arrangement provides for the sale of up to an aggregate of 60,000 shares of common stock, beginning on August 14, 2026 and ending on December 31, 2027 .
+Added: Termination of Vaccine Collaboration with CSL Seqirus
+Added: On August 3, 2026, we entered into the Termination Agreement with CSL Seqirus pursuant to which we mutually terminated the CSL Collaboration Agreement, effective as of such date.
+Added: Under the Termination Agreement, we received a one-time cash payment of $12.0 million from CSL Seqirus.
+Added: In addition, we were released from a liability and from repayment of an R&D credit with an aggregate value of approximately $16 million.
+Added: As a result of the termination, we regained strategic control of our vaccine portfolio, including KOSTAIVE ® and our vaccine programs for seasonal influenza, pandemic influenza, RSV and EBV, subject to ongoing arrangements with Meiji Seika Pharma (“Meiji”) for the Northern Hemisphere 2026-2027 season, which is expected to end on or around June 30, 2027.
+Added: Beginning with the Northern Hemisphere 2027–2028 season, we expect to work directly with Meiji for KOSTAIVE ® activities in Japan.
+Added: We are obligated to pay CSL Seqirus single-digit royalties and revenue-sharing payments on our future commercialization of vaccine products formerly licensed under the CSL Collaboration Agreement and successor products, where certain CSL Seqirus intellectual property is incorporated into such products, subject to agreed terms and conditions and applicable time limitations.
+Added: With respect to certain of the vaccine products, we are obligated to pay a percentage of upfront payments received from future licensees up to pre-agreed amounts.
+Added: As a result of the termination, we expect deferred revenue from CSL Seqirus of approximately $5.2 million associated with remaining performance obligations under the CSL Collaboration Agreement to be recognized during the third quarter of 2026.
+Added: In connection with the termination, the parties agreed to dismiss the arbitration and exchanged mutual releases of claims.
+Added: See “Part II – Other Information – Item 1.
+Added: Legal Proceedings” for more information.
+Added: The foregoing description of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Termination Agreement, a copy of which the Company intends to file with the Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Exhibit Index
16 unchanged sentences
Amended and Restated 2019 Omnibus Equity Incentive Plan.
−Removed: Incorporated by reference Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No.
+Added: Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No.
Arcturus Therapeutics Ltd.
106 unchanged sentences
Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on December 15, 2025 (File No.
+Added: Employment Agreement between Arcturus Therapeutics Holdings Inc.
+Added: and Dennis Mulroy dated April 27, 2026.
+Added: Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on May 7, 2026 (File No.
+Added: Master Services Agreement between Arcturus Therapeutics, Inc.
+Added: and Thermo Fisher Scientific Inc., dated June 26, 2026.
+Added: Project Addendum for Development Services between Arcturus Therapeutics, Inc.
+Added: and Patheon UK Limited, dated June 26, 2026.
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended.
4 unchanged sentences
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements and footnotes from the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline Extensible Business Reporting Language (Inline XBRL):
+Added: The following financial statements and footnotes from the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 formatted in Inline Extensible Business Reporting Language (Inline XBRL):
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
12 unchanged sentences
ARCTURUS THERAPEUTICS HOLDINGS INC.
−Removed: /s/ Joseph Roberts
−Removed: Joseph Roberts
−Removed: Interim Principal Finance and Accounting Officer, Controller
+Added: August 6, 2026
+Added: /s/ Dennis Mulroy
+Added: Dennis Mulroy
+Added: Chief Financial Officer
+Added: Principal Financial and Accounting Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.